Renaissance Technologies’s BSX Holdings & Trades

First Buy
Q2 2013
Duration Held
50 Quarters
Largest Add
Q2 2013
+10.34 M Shares
Current Position
917,105 Shares
$89.54 M Value

Renaissance Technologies's BSX Position Overview

Renaissance Technologies (via Renaissance Technologies LLC) currently holds 917,105 shares of Boston Scientific Corporation (BSX) worth $89.54 M, representing 0.12% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.

Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in BSX, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2016, adding 4.28 M shares. Largest reduction occurred in Q3 2013, reducing 5.54 M shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies's Boston Scientific Corporation (BSX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Boston Scientific Corporation (BSX) Trades by Renaissance Technologies

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2013 +10.34 M Add 0.00% 10.34 M $9.27
Q3 2013 -5.54 M Reduce 53.54% 4.8 M $11.74
Q4 2013 -444,885 Reduce 9.26% 4.36 M $12.02
Q1 2014 -2.86 M Reduce 65.71% 1.49 M $13.52
Q2 2014 -954,200 Reduce 63.85% 540,205 $12.77
Q3 2014 +1.67 M Add 309.09% 2.21 M $11.81
Q4 2014 +3.12 M Add 141.34% 5.33 M $13.25
Q1 2015 -1.54 M Reduce 28.87% 3.79 M $17.75
Q2 2015 -946,350 Reduce 24.95% 2.85 M $17.70
Q3 2015 -2.85 M Sold Out 2.85 M $0.00
Q4 2015 +3.47 M New Buy 3.47 M $18.44
Q1 2016 -2.85 M Reduce 82.19% 618,405 $18.81
Q2 2016 +4.28 M Add 692.67% 4.9 M $23.37
Q3 2016 -3.02 M Reduce 61.57% 1.88 M $23.80
Q4 2016 +741,300 Add 39.35% 2.63 M $21.63
Q1 2017 +3.1 M Add 118.13% 5.73 M $24.87
Q2 2017 -421,100 Reduce 7.35% 5.31 M $27.72
Q3 2017 -3.29 M Reduce 62.07% 2.01 M $29.17
Q4 2017 -866,100 Reduce 43.04% 1.15 M $24.79
Q1 2018 -52,000 Reduce 4.54% 1.09 M $27.32
Q2 2018 -1.09 M Sold Out 1.09 M $0.00
Q1 2019 +2.19 M New Buy 2.19 M $38.38
Q2 2019 -2.07 M Reduce 94.58% 118,829 $42.98
Q3 2019 -118,829 Sold Out 118,829 $0.00
Q2 2020 +27,605 New Buy 27,605 $35.10
Q3 2020 -27,605 Sold Out 27,605 $0.00
Q4 2020 +2.77 M New Buy 2.77 M $35.95
Q1 2021 -2.77 M Sold Out 2.77 M $0.00
Q2 2023 +835,905 New Buy 835,905 $0.05
Q3 2023 -835,905 Sold Out 835,905 $0.00
Q3 2024 +258,025 New Buy 258,025 $83.80
Q4 2024 -258,025 Sold Out 258,025 $0.00
Q1 2025 +651,553 New Buy 651,553 $100.88
Q2 2025 +844,988 Add 129.69% 1.5 M $107.41
Q3 2025 -579,436 Reduce 38.72% 917,105 $97.63

Renaissance Technologies's Boston Scientific Corporation Investment FAQs

Renaissance Technologies first purchased Boston Scientific Corporation (BSX) in Q2 2013, acquiring 10,339,305 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies has held Boston Scientific Corporation (BSX) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies's largest addition to Boston Scientific Corporation (BSX) was in Q2 2013, adding 10,339,305 shares worth $95.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 917,105 shares of Boston Scientific Corporation (BSX), valued at approximately $89.54 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Boston Scientific Corporation (BSX) represents approximately 0.12% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies's peak holding in Boston Scientific Corporation (BSX) was 10,339,305 shares, as reported at the end of Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.